HOW NEMLUVIO WORKS FOR ECZEMA

Clearer skin from the inside out* Clear skin from the inside out*

Not an actual patient.

NEMLUVIO® is the first and only treatment that blocks IL-31 signaling, a key driver of itch, inflammation, and rashes caused by eczema (atopic dermatitis). By relieving itch and reducing the urge to scratch, NEMLUVIO allows your skin to clear.1,2

NEMLUVIO® is the first and only treatment that blocks IL-31 signaling, a key driver of itch, inflammation, and rashes caused by eczema (atopic dermatitis). By relieving itch and reducing the urge to scratch, NEMLUVIO allows your skin to clear.1,2

Get the relief you’ve been waiting for with NEMLUVIO

Fast itch relief as soon 
as 48 hours3†

Long-lasting3 
skin clearance3

Fewer sleepless
nights1‡

Favorable
safety profile1

~Once-monthly dosing 
from the start1

>75% less liquid volume per injection than dupilumab1‡

Who is NEMLUVIO for?

NEMLUVIO is intended for adults and adolescents 
(age 12 or older) with moderate-to-severe eczema that is not well controlled by current treatments.1

If you have signs of eczema, or your symptoms feel out of control, talk to your dermatologist about NEMLUVIO.

Sign up now to learn more about NEMLUVIO and see if it's right for you.

SIGN UP  

Not an actual patient.

How does NEMLUVIO work?

Discover how NEMLUVIO works below the surface of the skin to relieve itch and the urge to scratch.1

Success with NEMLUVIO starts here

Understand what to expect throughout your experience with NEMLUVIO. Explore the guides, instructions for use, and other supportive resources.

VIEW RESOURCES  

Not an actual patient.

clearer skin that lasts

From Week 16 and beyond, learn how NEMLUVIO was proven  to clear the rashes of eczema.3

Individual results may vary.

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post hoc descriptive analysis of daily PP-NRS 
improvement; consistent results seen in ARCADIA 2. Significant improvement was achieved at 48 hours (9% with NEMLUVIO + TCS/TCI vs 3% with placebo + TCS/TCI, P≤0.001).1,3

In clinical trials, adults and adolescents reported sleeping better while on treatment with NEMLUVIO for eczema.1

IL-31=Interleukin-31; PP-NRS=Peak Pruritus Numerical Rating Scale; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.

References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 2. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. doi:10.3389/fmed.2021.639097 3. Galderma Laboratories, L.P.; data on file. 4. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835-852. doi:10.1080/1744666X.2021.1940962 5. Hänel KH, Pfaff CM, Cornelissen C, et al. Control of the physical and antimicrobial skin barrier by an IL-31-IL-1 signaling network. J Immunol. 2016;196(8):3233-3244. doi:10.4049/jimmunol.1402943

Important Safety Information

Indications: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used:

  • to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age.
  • to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age.

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO. Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:

  • are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
  • are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

  • Breathing problems or wheezing
  • Swelling of the face, lips, mouth, tongue, or throat
  • Fainting, dizziness, feeling lightheaded
  • Fast pulse
  • Swollen lymph nodes
  • Joint pain
  • Fever
  • Skin rash (red or rough skin)
  • Nausea or vomiting
  • General ill feeling
  • Cramps in your stomach area

The most common side effects of NEMLUVIO include:

  • Eczema: headache, joint pain, hives (itchy red rash or wheals), and muscle aches
  • Prurigo Nodularis: headache and skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches)

These are not all of the possible side effects of NEMLUVIO.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.